MedPath

Immune checkpoint inhibitors for ocular melanoma

Not Applicable
Conditions
Ocular melanoma
Registration Number
JPRN-UMIN000047431
Lead Sponsor
Yokohama City University Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with ocular melanoma who were treated with ICI as adjuvant/neoadjuvant therapy

Study & Design

Study Type
Others,meta-analysis etc
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ORR, DCR, PFS, and OS among patients with ocular melanoma who were treated with ICI.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath